MM 07 (Synonyms: Cys-Arg-Pro-Arg-Leu-Cys-His-Lys-Gly-Pro-Met-Pro-Phe (Disulfide bridge:Cys1-Cys6)) |
| Catalog No.GC32475 |
MM 07 is an apelin-biased receptor agonist with KD of 300 nM in CHO-K1 cells and 172 nM in human heart.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1876450-21-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
MM 07 is an apelin-biased receptor agonist with KD of 300 nM in CHO-K1 cells and 172 nM in human heart.
MM 07 competes with nanomolar affinity for binding to [Glp65,Nle75,Tyr77] [125I]apelin-13 is receptor-dependent on human apelin in CHO-K1 cells (KD, 300 nM) and human heart (KD, 172 nM, n=3). body [1].
MM 07 caused a dose-dependent increase in cardiac output with no corresponding effect on blood pressure despite a decrease in vascular resistance. In both the [Pyr1]apelin-13 and MM 07-treated groups, SNAP administration resulted in a significant decrease in blood pressure; however, while SNAP-responsive cardiac output was significantly increased in the MM 07 group, the [Pyr1]apelin-13 group Cardiac output is significantly reduced. Neither peptide caused significant changes in heart rate, breathing rate or temperature. [Pyr1] Both apelin 13 and MM 07 increase the peak speed above the base level [1].
References:
[1]. Brame AL et al. Design, characterization, and first-in-human studies of a novel biased apelin receptor agonist for vascular effects. hypertension. 2015 Apr;65(4):834-40.
|
Animal experiment: |
Rats[1]Rats (230-260 g), anaesthetized with 2% isoflurane, are given a single intravenous bolus (600 nM) of apelin or MM 07 (both n=3)[1]. |
|
References: [1]. Brame AL, et al. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension. 2015 Apr;65(4):834-40. |
|
| Cas No. | 1876450-21-3 | SDF | |
| Synonyms | Cys-Arg-Pro-Arg-Leu-Cys-His-Lys-Gly-Pro-Met-Pro-Phe (Disulfide bridge:Cys1-Cys6) | ||
| Formula | C₆₇H₁₀₆N₂₂O₁₄S₃ | M.Wt | 1539.89 |
| Solubility | DMSO : 62.5 mg/mL (40.59 mM; Need ultrasonic) | Storage | Store at -20° C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.6494 mL | 3.247 mL | 6.494 mL |
| 5 mM | 0.1299 mL | 0.6494 mL | 1.2988 mL |
| 10 mM | 0.0649 mL | 0.3247 mL | 0.6494 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *